Aridis Phar­ma seeks $35M to fight in­fec­tions with im­munother­a­pies — lat­est in an IPO streak

Get­ting ready for its first Phase III tri­al, Aridis Phar­ma is now turn­ing to pub­lic in­vestors to sup­port its pathogen-spe­cif­ic im­munother­a­pies in a mod­est $35 mil­lion IPO.

San Jose, CA-based Aridis joins an ever-grow­ing crowd of biotechs look­ing to cash in on the bull­ish sen­ti­ment on dis­play on Nas­daq. Their pitch: a port­fo­lio of ful­ly hu­man mon­o­clon­al an­ti­bod­ies treat life-threat­en­ing in­fec­tions such as hos­pi­tal-ac­quired pneu­mo­nia (HAP) and ven­ti­la­tor-as­so­ci­at­ed pneu­mo­nia (VAP), de­vel­oped from a pro­pri­etary dis­cov­ery plat­form.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER